Already a Bloomberg.com user?
Sign in with the same account.
Don't have an account?
Help! I can't access my account.
July 17 (Bloomberg) -- Novartis AG raised its full-year forecast as generic competition for the Diovan blood-pressure drug failed to materialize in the U.S. Sam Fazeli reports on Bloomberg Television's "Countdown." (Source: Bloomberg)
On Air Now
In The Loop with Betty Liu
©2014 Bloomberg L.P. All Rights Reserved. Made in NYC